BioCentury
ARTICLE | Company News

Pfizer gets U.S. rights to Synthon's generic Copaxone

August 4, 2015 12:53 AM UTC

Synthon B.V. (Nijmegen, the Netherlands) granted Pfizer Inc. (NYSE:PFE) exclusive U.S. commercialization rights to a generic version of glatiramer acetate for relapsing/remitting multiple sclerosis. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) markets Copaxone glatiramer acetate.

The deal, for which terms were not disclosed, includes Synthon's once-daily and thrice-weekly formulations of glatiramer. Both are under FDA review. Synthon said it believes the thrice-weekly version "may be eligible for 180 days of shared marketing exclusivity" under Hatch-Waxman, but Pfizer spokesperson MacKay Jimeson declined to clarify who would share the rights, and would not tell BioCentury whether Pfizer or Synthon is planning to challenge Teva's U.S. patent on the thrice-weekly formulation. ...